Accumulation of major linezolid metabolites in patients with renal impairment.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY(2020)
摘要
In patients with renal impairment (n = 22 of 39), the median serum concentrations of linezolid, PNU-142300, and PNU-142586 were 1.6-, 3.3-, 2.8-fold higher, respectively, than in patients without renal impairment. Metabolite concentrations in paired samples were poorly correlated with linezolid concentrations (r(2) = 0.26 for PNU-142300 and 0.06 for PNU-142586). Linezolid and its metabolites share potential toxicophores that deserve characterization to mitigate higher myelosuppression risk in patients with renal impairment.
更多查看译文
关键词
dialysis,myelosuppression,oxazolidinones,pharmacodynamics,toxicology
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要